>Another strong contribution from the flexible generation activity in Q1 - Uniper released its Q1 results this morning. EBITDA was € 885m (-11%) a shade below our forecast of € 900m (ODDO BHF estimates). EBIT also declined to € 732m (-4%) but was above our forecast at € 710m benefiting from a lower depreciation level. In the end, net income increased to € 570m (+26%) in line with our forecast of € 560m, marked by improved interest income and a low tax rate. By divisio...
>Solid order intake – EBITDA broadly in line - Q1 2024 came in broadly in line with the consensus estimates with a sluggish start to the year at P&L level and, on the other hand, a dynamic order intake. The importance of Q1 needs to be put into perspective, as the quarter represents only 8% of the expected EBITDA based on the middle of the guidance range. Adjusted EBITDA was up 10.7% to € 33m thanks to favourable project mix effects (ODDO BHF: € 32.3m; compan...
Two Directors at Barco NV bought 136,190 shares at 13.000EUR. The significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly sho...
A director at Castellum AB bought 3,633 shares at 126.950SEK and the significance rating of the trade was 42/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly ...
Four Directors at Thomson Reuters Corp sold 7,686 shares at between 164.400USD and 168.120USD. The significance rating of the trade was 73/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors ov...
A director at Nick Scali bought 25,000 shares at 14.693AUD and the significance rating of the trade was 82/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly sh...
A director at Scandi Standard AB bought 100,000 shares at 72.250SEK and the significance rating of the trade was 81/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years c...
>Group revenue in line, EBIT margins above estimate - Berentzen reported Q1 2024 revenue of € 40.9m (in line with ODDO BHF) but slightly down y-o-y. The reason for the decline was that 1) the cooperation business with prominent artists in the Non-alcoholic Beverages segment was terminated last year and 2) several high-revenue marketing campaigns were not conducted in the first three months of 2024 due to difficult price negotiations with some key retail partners. The...
The Bulgarian equity market exhibited some downside actions on Thursday in this short and abrupt week as First Investment Bank (FIB, BGN 3.10, +10.71%) impacted the overall picture and settled SOFIX (813.65, +0.01%) on a note higher. The broad indexes BGBX40 (165.13, -0.15%) and BGTR30 (817.49, -0.02%) reflected the selloffs of Eleven Capital (11C, BGN 15.00, -7.93%) and M+S Hydraulic (MSH, BGN 11.40, -3.39%). The volumes unexpectedly exceeded previous day ones but closed below the 15-days avera...
A director at Trivago NV sold 10,374 shares at 2.419USD and the significance rating of the trade was 52/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showi...
>Strong Q1 2024 results - This morning, Elmos reported Q1 2024 results that beat expectations. Revenues were € 136.8m, above the consensus at € 135.4m. They were up 4.5% y-o-y but down 13% q-o-q. EBIT came in at € 33.8m, giving an EBIT margin of 24.7% above the consensus at € 31.7m and 23.4%. EPS was € 1.44 above consensus at € 1.27. Adjusted free cash flow stood at -€ 48.9m (vs € 35m in Q4 2023) impacted by year-end effects on working capital. Capex came in at € 20.3...
>Strong Q1 2024 results - This morning, Elmos reported Q1 2024 results that beat expectations. Revenues were € 136.8m, above the consensus at € 135.4m. They were up 4.5% y-o-y but down 13% q-o-q. EBIT came in at € 33.8m, giving an EBIT margin of 24.7% above the consensus at € 31.7m and 23.4%. EPS was € 1.44 above consensus at € 1.27. Adjusted free cash flow stood at -€ 48.9m (vs € 35m in Q4 2023) impacted by year-end effects on working capital. Capex came in at € 20.3...
Medios reported Q1 2024 results with revenue increasing 5.8% to EUR 456.2m led by 8.9% growth coming from the Pharmaceutical Supply (PS) segment, of which sales amounted to EUR 401m (EUR 368.1m), while the Patient-Specific Therapies (PTS) segment suffered from the 12.4% decline due to the divestmen
BICO has reported Q1 2024 net sales amounting to SEK 510.3m (+2% vs. css) implying 4.4% YoY growth and organic growth of 4.7% (-1.1%). The Biosciences segment outperformed with net sales showing 36.3% organic growth to SEK 310m (SEK 230m), while Bioprinting and Bioautomation fell short of expectati
>Q2 review – Miss on top and bottom line - Coloplast’s Q2 2024 revenues of DKK 6,586m (+8.7% y-o-y) were -1%/-2% vs ODDO BHF/consensus, driven by organic growth of 8% (7.3%/7.6% ODDO BHF/consensus). External growth contributed to the tune of 4% and forex created a headwind of 300bp. Coloplast achieved an EBIT of DKK 1,772m (+7.3% y-o-y, margin 26.9%), which was -3%/-4% vs expectations. Profitability was supported by operating leverage and efficiency savings but impact...
Syngenta Group / Key word(s): Miscellaneous Syngenta extends leadership in fungicides with ADEPIDYN® technology 07.05.2024 / 09:00 CET/CEST ADEPIDYN® technology on track to be first of Syngenta’s crop protection active ingredients to attain billion-dollar annual sales within eight years of commercialization Following registration approval in Great Britain, farmers in more than 55 countries now have access to this powerful fungicide Success reflects Syngenta’s innovation leadership in fungicides and the SDHI mode of action, and in bringing to market products with strong su...
EQS-News: Biotest AG / Schlagwort(e): Quartalsergebnis Biotest steigert Umsatz im ersten Quartal 2024 um 83,6% auf 215,2 Mio. Euro 07.05.2024 / 09:00 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. PRESSEMITTEILUNG Biotest steigert Umsatz im ersten Quartal 2024 um 83,6% auf 215,2 Mio. Euro Umsatz mit Produkten stieg um 17,7 % auf 138,0 Mio. Euro EBIT gesteigert auf 52,8 Mio. Euro Fibrinogenstudie erfolgreich abgeschlossen Dreieich, 07. Mai 2024. Im ersten Quartal des Geschäftsjahres 2024 verzeichnete die Biotest Gr...
EQS-News: Biotest AG / Key word(s): Quarter Results Biotest increased sales by 83.6% to Euro 215.2 million in first quarter 2024 07.05.2024 / 09:00 CET/CEST The issuer is solely responsible for the content of this announcement. PRESS RELEASE Biotest increased sales by 83.6% to Euro 215.2 million in first quarter 2024 Product sales increased by 17.7% to Euro 138.0 million EBIT increased to Euro 52.8 million Successful completion Fibrinogen study Dreieich, 07 May 2024. The Biotest Group recorded revenue of € 215.2 million in the first quarter of the 202...
1/4NEWSContact:東京 東京円城 ディーン セメトコ 真理子主任格付アナリスト/VPシニア・アナリスト 格付責任者/アソシエイト・マネージング・ディレクターコーポレート・ファイナンス・グループ コーポレート・ファイナンス・グループムーディーズ・ジャパン株式会社 ムーディーズ・ジャパン株式会社お客様専用電話番号:03-5408-4100報道関係者電話番号:03-5408-4110お客様専用電話番号:03-5408-4100報道関係者電話番号:03-5408-4110[MJKK]ダイキンの国内発行登録枠に(P)A2の予備格付を付与 2024年5月7日、東京、ムーディーズ・ジャパ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.